Collegium Pharmaceutical Inc (NASDAQ:COLL) shares shot up 0% during trading on Monday after Jefferies Group raised their price target on the stock to $32.00. Jefferies Group currently has a buy rating on the stock. Collegium Pharmaceutical traded as high as $25.91 and last traded at $23.62. 1,910,000 shares were traded during mid-day trading, an increase of 208% from the average session volume of 619,791 shares. The stock had previously closed at $23.62.
Several other brokerages have also recently commented on COLL. Piper Jaffray Companies set a $33.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, January 23rd. BidaskClub cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Needham & Company LLC raised their target price on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Janney Montgomery Scott set a $26.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $27.17.
In related news, insider Alison B. Fleming sold 4,601 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total transaction of $79,367.25. Following the transaction, the insider now owns 28,513 shares of the company’s stock, valued at $491,849.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00. Following the transaction, the chief executive officer now directly owns 558,987 shares in the company, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,105,558 shares of company stock valued at $19,346,677. 25.76% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Benjamin F. Edwards & Company Inc. raised its position in Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,500 shares in the last quarter. Acadian Asset Management LLC bought a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $176,000. Voya Investment Management LLC bought a new position in Collegium Pharmaceutical during the second quarter valued at approximately $125,000. Nationwide Fund Advisors raised its position in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 2,802 shares in the last quarter. Finally, Monarch Partners Asset Management LLC bought a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $264,000. 82.40% of the stock is currently owned by hedge funds and other institutional investors.
The firm has a market cap of $769.12 and a PE ratio of -7.95.
WARNING: “Collegium Pharmaceutical (COLL) Shares Up 0% Following Analyst Upgrade” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/12/collegium-pharmaceutical-coll-shares-up-0-following-analyst-upgrade.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.